Carcinoma News and Research

RSS
Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.
Physicians have new resource for managing disease in patients with early-stage breast cancer

Physicians have new resource for managing disease in patients with early-stage breast cancer

Discovery sheds new light on aggressiveness of certain breast cancers

Discovery sheds new light on aggressiveness of certain breast cancers

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

University of Sheffield researchers show how human skin constantly regrows

University of Sheffield researchers show how human skin constantly regrows

Advaxis seeks ADXS-HPV Orphan Drug Designation for treatment of HPV-associated anal cancer

Advaxis seeks ADXS-HPV Orphan Drug Designation for treatment of HPV-associated anal cancer

Investigators uncover connection between tumor metabolic process and progression of kidney cancer

Investigators uncover connection between tumor metabolic process and progression of kidney cancer

Stress exposure may be associated with increased risk of aggressive breast cancer

Stress exposure may be associated with increased risk of aggressive breast cancer

Research findings could enable early screening of HCC patients for more aggressive treatment

Research findings could enable early screening of HCC patients for more aggressive treatment

Research could enable early screening of liver cancer patients to improve survival rate

Research could enable early screening of liver cancer patients to improve survival rate

Esophageal cancer: A serious threat to African-American men

Esophageal cancer: A serious threat to African-American men

Combination of cytoreductive surgery and HIPEC may reduce mortality in abdominal cancers patients

Combination of cytoreductive surgery and HIPEC may reduce mortality in abdominal cancers patients

OncoSec Medical signs Sponsored Research Agreement with ODU for melanoma study

OncoSec Medical signs Sponsored Research Agreement with ODU for melanoma study

AVEO Oncology receives Complete Response letter from FDA for tivozanib NDA

AVEO Oncology receives Complete Response letter from FDA for tivozanib NDA

Ingenol mebutate drug does not offer added benefit over diclofenac/hyaluronic acid gel

Ingenol mebutate drug does not offer added benefit over diclofenac/hyaluronic acid gel

Data from Nivolumab phase I study in patients with kidney cancer to be presented at ASCO 2013

Data from Nivolumab phase I study in patients with kidney cancer to be presented at ASCO 2013

Researchers develop RNA aptamers that inhibit HCV replication

Researchers develop RNA aptamers that inhibit HCV replication

Study supports future possibility of personalized medicine for cervical cancer

Study supports future possibility of personalized medicine for cervical cancer

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

Raman spectroscopy algorithm has potential to diagnose breast lesions with high precision

Raman spectroscopy algorithm has potential to diagnose breast lesions with high precision

Tafinlar, Mekinist get FDA approval to treat patients with advanced melanoma

Tafinlar, Mekinist get FDA approval to treat patients with advanced melanoma

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.